NewsBenzingaOpus Genetics präsentiert klinische Ergebnisse aus den Gentherapie-Programmen OPGx-BEST1 und OPGx-LCA5 auf der Retina in Rio 2026; die Dosierung in der klinischen Phase-3-Studie für OPGx-LCA5 wird im 4. Quartal 2026 erwartet Opus Genetics präsentiert klinische Ergebnisse aus den Gentherapie-Programmen OPGx-BEST1 und OPGx-LCA5 auf der Retina in Rio 2026; die Dosierung in der klinischen Phase-3-Studie für OPGx-LCA5 wird im 4. Quartal 2026 erwartet Benzinga 2026.10.15 20:02 (GMT+0) Open on Benzinga Other news 'Trump Grows Frustrated With Vance Over Iran War Critique'- New York Times Why Is Salesforce Stock Falling on Wednesday? This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Ford Ships First Battery Cells from Michigan Plant for Fathom Electric Pickup; Key Milestone for Ford Energy Bill Ackman Says Believes Board Not Acting In Best Interest Of Shareholders Nor In A Manner Consistent With Their Fiduciary Duties; Should Have Slept On Decision To Replace Jensen Huang And Met Again The Day After To Discuss The Facts Crude Oil Down Over 4%; Target Earnings Top Views
Ford Ships First Battery Cells from Michigan Plant for Fathom Electric Pickup; Key Milestone for Ford Energy
Bill Ackman Says Believes Board Not Acting In Best Interest Of Shareholders Nor In A Manner Consistent With Their Fiduciary Duties; Should Have Slept On Decision To Replace Jensen Huang And Met Again The Day After To Discuss The Facts